This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons ...

We evaluate cancer-protective effects of walnuts via formation of microbe-derived urolithin A, substantiating their functional benefits on serum inflammatory markers and immunologic composition of ...

Aberrant activation of ERBB family members through various mechanisms plays a crucial role in the development and progression of a variety of cancer types ().Overexpression of HER2, due to ERBB2 ...

The 5-year survival rate for pancreatic ductal adenocarcinoma (PDA) is currently 13%, making it one of the most fatal human malignancies; to date, PDA is the third leading cause of cancer-related ...

AbstractPurpose:. Elacestrant significantly prolonged progression-free survival (PFS) with manageable safety versus standard-of-care (SOC) endocrine therapy (ET) in patients with estrogen ...

Abstract. Endocrine therapies (ET) with cyclin-dependent kinase 4/6 (CDK4/6) inhibition are the standard treatment for estrogen receptor-α-positive (ER+) breast cancer, however drug resistance is ...

Proleukin is an FDA-approved formulation of recombinant human IL2 that can be intravenously (IV) administered at high doses for the treatment of metastatic melanoma and metastatic renal cell carcinoma ...

AbstractPurpose:. The DIANA-5 randomized controlled trial assessed the effectiveness of a diet based on Mediterranean and macrobiotic traditions (macro-Mediterranean diet) in reducing breast cancer ...

AbstractPurpose:. Peposertib—an orally administered DNA-dependent protein kinase inhibitor—has shown potent radiosensitization in preclinical models. This dose-escalation study (NCT03770689) aimed to ...

Immunotherapy, particularly immune-checkpoint inhibitors (ICI), has become a standard treatment for many types of cancer ().The anti-programmed death-1 (PD-1) monoclonal antibody pembrolizumab is ...

AbstractPurpose:. Cachexia is common in patients with advanced cancer and is associated with elevated serum growth differentiation factor 15 (GDF-15) concentrations. This first-in-patient (phase Ib), ...